# CMND catalysts: Clearmind Medicine Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/cmnd/catalysts

> Clearmind Medicine Inc. (CMND) has no upcoming catalysts in this calendar. The latest recorded is the CMND-100 topline data readout, February 9, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Clearmind Medicine Inc. |
| Ticker | CMND (Nasdaq) |
| SEC CIK | 1892500 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/cmnd |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Feb 2024 | [CMND-100 FDA approval](https://sec-api.dev/pdufa/cmnd-100) | CMND |  | completed, approved | "In February 2024 and in July 2024, the Company announced that it was granted approval by the Israeli Ministry of Health and by the U.S. Food and Drug Administration, respectively to initiate its first-in-human Phase I/IIa clinical trial with CMND-100 in patients suffering from AUD." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1892500/000121390026098779/ea030403301ex99-2.htm)) |
| March 18, 2025 | [CMND-100 trial start](https://sec-api.dev/pdufa/cmnd-100) | CMND |  | completed | "Canada, March 18, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces today that it initiated its Phase I/IIa clinical trial investigating the safety, tolerability and full pharmacokinetic profile of its innovative treatment, CMND-100, in Alcohol Use Disorder (AUD) patients." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1892500/000101376225000571/ea023459001ex99-1_clearmind.htm)) |
| April 30, 2025 | [CMND-100 FDA approval](https://sec-api.dev/pdufa/cmnd-100) | CMND |  | completed, approved | "2024, the Company announced that it was granted approval by the Israeli Ministry of Health and by the FDA, respectively to initiate its first-in-human Phase I/IIa clinical trial with CMND-100 in patients suffering from AUD." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1892500/000121390025053839/ea024453601ex99-2_clearmind.htm)) |
| July 31, 2025 | [CMND-100 FDA approval](https://sec-api.dev/pdufa/cmnd-100) | CMND |  | completed, approved | "2024, the Company announced that it was granted approval by the Israeli Ministry of Health and by the FDA, respectively to initiate its first-in-human Phase I/IIa clinical trial with CMND-100 in patients suffering from AUD." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1892500/000121390025086821/ea025617001ex99-2_clearmind.htm)) |
| November 18, 2025 | [CMND-100 topline data readout](https://sec-api.dev/pdufa/cmnd-100) | CMND | Alcohol Use Disorder | completed, positive | "Canada, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced positive top-line results from the first cohort of its Phase I/IIa clinical trial evaluating CMND-100, the Company's proprietary non-hallucinogenic MEAI-based oral drug candidate for the treatment of Alcohol Use Disorder (AUD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1892500/000121390025112114/ea026618401ex99-1_clearmind.htm)) |
| February 9, 2026 | [CMND-100 topline data readout](https://sec-api.dev/pdufa/cmnd-100) | CMND |  | completed, positive | "Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced additional positive safety topline results from the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1892500/000121390026013478/ea027611302ex99-1_clearmind.htm)) |

## Drugs

- [CMND-100](https://sec-api.dev/pdufa/cmnd-100): alcohol use disorder

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/cmnd/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CMND catalysts: Clearmind Medicine Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/cmnd/catalysts

```bibtex
@misc{secapidev_companies_cmnd_catalysts_20261116,
  title        = {CMND catalysts: Clearmind Medicine Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/cmnd/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_cmnd_catalysts_20261116","title":"CMND catalysts: Clearmind Medicine Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/cmnd/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
